Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers.
Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X. Nome ME, et al. Among authors: tekpli x. Int J Cancer. 2020 Jan 1;146(1):223-235. doi: 10.1002/ijc.32638. Epub 2019 Oct 8. Int J Cancer. 2020. PMID: 31444972 Free article. Clinical Trial.
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer.
von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O. von der Lippe Gythfeldt H, et al. Among authors: tekpli x. Int J Cancer. 2020 Nov 1;147(9):2515-2525. doi: 10.1002/ijc.33108. Epub 2020 Jun 18. Int J Cancer. 2020. PMID: 32488909 Free article. Clinical Trial.
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab.
Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Lüders T, von der Lippe Gythfeldt H, Troyanskaya O, Kyte JA, Børresen-Dale AL, Naume B, Tekpli X, Engebraaten O, Kristensen V. Jabeen S, et al. Among authors: tekpli x. Oncoimmunology. 2018 Aug 6;7(11):e1457598. doi: 10.1080/2162402X.2018.1457598. eCollection 2018. Oncoimmunology. 2018. PMID: 30377556 Free PMC article.
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics.
Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Lüders T, Engebraaten O, Børresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X. Jabeen S, et al. Among authors: tekpli x. Oncoimmunology. 2018 Nov 5;8(2):e1537691. doi: 10.1080/2162402X.2018.1537691. eCollection 2019. Oncoimmunology. 2018. PMID: 30713794 Free PMC article.
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment.
Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø; OSBREAC; Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN. Tekpli X, et al. Nat Commun. 2019 Dec 3;10(1):5499. doi: 10.1038/s41467-019-13329-5. Nat Commun. 2019. PMID: 31796750 Free PMC article.
DNA methylation at enhancers identifies distinct breast cancer lineages.
Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E; Oslo Breast Cancer Research Consortium (OSBREAC); Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN. Fleischer T, et al. Among authors: tekpli x. Nat Commun. 2017 Nov 9;8(1):1379. doi: 10.1038/s41467-017-00510-x. Nat Commun. 2017. PMID: 29123100 Free PMC article.
53 results